Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort

PURPOSE: We aim to describe the treatment patterns and overall survival (OS) outcomes in patients receiving trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer (HER2+MBC) in routine clinical care. METHODS: Retrospective, whole-of-population cohort study of people initiating T-DM...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniels, Benjamin, Kiely, Belinda E., Tang, Monica, Houssami, Nehmat, Lord, Sarah J., Pearson, Sallie-Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138859/
https://www.ncbi.nlm.nih.gov/pubmed/33992964
http://dx.doi.org/10.1016/j.breast.2021.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138859/
https://www.ncbi.nlm.nih.gov/pubmed/33992964
http://dx.doi.org/10.1016/j.breast.2021.05.001

Ejemplares similares